Compare SBSI & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SBSI | ESPR |
|---|---|---|
| Founded | 1960 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 920.2M | 898.5M |
| IPO Year | N/A | 2013 |
| Metric | SBSI | ESPR |
|---|---|---|
| Price | $32.22 | $3.09 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $33.50 | $6.67 |
| AVG Volume (30 Days) | 109.7K | ★ 5.6M |
| Earning Date | 01-29-2026 | 03-03-2026 |
| Dividend Yield | ★ 4.46% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.30 | N/A |
| Revenue | $236,346,000.00 | ★ $303,802,000.00 |
| Revenue This Year | $11.41 | $26.11 |
| Revenue Next Year | $5.33 | N/A |
| P/E Ratio | $14.03 | ★ N/A |
| Revenue Growth | N/A | ★ 2.83 |
| 52 Week Low | $25.85 | $0.69 |
| 52 Week High | $33.14 | $4.18 |
| Indicator | SBSI | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 62.98 | 32.93 |
| Support Level | $31.11 | $3.00 |
| Resistance Level | $32.67 | $4.18 |
| Average True Range (ATR) | 0.62 | 0.23 |
| MACD | 0.06 | -0.11 |
| Stochastic Oscillator | 83.14 | 4.26 |
Southside Bancshares Inc is a bank holding company. Through its subsidiary, the Southside Bank, it operates as a financial institution offering various financial services to individuals, businesses, municipal entities, and nonprofit organizations. These services include consumer and commercial loans, deposit accounts, wealth management and trust services, brokerage services, and safe deposit services. The company's primary market areas are East Texas, Southeast Texas, and the greater Dallas-Fort Worth, Austin, and Houston, Texas.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.